OJEMDA
Total Payments
$703,048
Transactions
441
Doctors
101
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $703,048 | 441 | 101 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $511,343 | 250 | 72.7% |
| Consulting Fee | $116,615 | 32 | 16.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $50,310 | 15 | 7.2% |
| Travel and Lodging | $15,829 | 30 | 2.3% |
| Food and Beverage | $5,951 | 113 | 0.8% |
| Space rental or facility fees (teaching hospital only) | $3,000 | 1 | 0.4% |
Payments by Type
Research
$511,343
250 transactions
General
$191,705
191 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations | Day One Biopharmaceuticals | $313,784 | 0 |
| DAY101-001/PNOC026: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients with RAF Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors | Day One Biopharmaceuticals | $131,823 | 0 |
| LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy | Day One Biopharmaceuticals | $65,736 | 0 |
Top Doctors Receiving Payments for OJEMDA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Phila, PA | $514,343 | 251 |
| , MD | Pediatric Hematology-Oncology | Oakland, CA | $34,246 | 26 |
| , M.D | Student in an Organized Health Care Education/Training Program | Durham, NC | $27,934 | 11 |
| , MD | Pediatric Hematology-Oncology | Orlando, FL | $20,091 | 9 |
| , NP | Anesthesiology | Durham, NC | $17,738 | 23 |
| , MD | Pediatrics | Saint Louis, MO | $9,210 | 9 |
| , MD | Pediatric Hematology-Oncology | Jackson, MS | $6,546 | 7 |
| , MD | Pediatrics | Los Angeles, CA | $5,525 | 2 |
| , DO | Neurology | Philadelphia, PA | $4,500 | 1 |
| , MD | Pediatrics | Philadelphia, PA | $3,500 | 1 |
| , ARNP | Pediatrics | Seattle, WA | $3,233 | 6 |
| , MD | Pediatric Hematology-Oncology | Houston, TX | $3,201 | 2 |
| , MD | Pediatric Hematology-Oncology | Chicago, IL | $3,195 | 1 |
| , MD | Pediatric Hematology-Oncology | Washington, DC | $3,195 | 1 |
| , MD | Pediatric Hematology-Oncology | Los Angeles, CA | $3,150 | 1 |
| , M.D | Medical Oncology | Baltimore, MD | $3,150 | 1 |
| , MD | Pediatrics | Ann Arbor, MI | $3,075 | 1 |
| , M.D | Ophthalmology | Milwaukee, WI | $2,880 | 1 |
| Jessica Clymer | Pediatric Hematology-Oncology | Boston, MA | $2,725 | 1 |
| , MD | Neurology | Boston, MA | $2,680 | 1 |
| Richard Drachtman | Pediatrics | New Brunswick, NJ | $2,600 | 1 |
| , MD | Pediatric Dermatology | Chicago, IL | $2,600 | 1 |
| , M.D | Student in an Organized Health Care Education/Training Program | Tampa, FL | $2,571 | 2 |
| , M.D | Pediatrics | San Diego, CA | $2,475 | 1 |
| , MD | Pediatric Hematology-Oncology | Washington, DC | $2,460 | 1 |
Ad
Manufacturing Companies
- Day One Biopharmaceuticals $703,048
Product Information
- Type Drug
- Total Payments $703,048
- Total Doctors 101
- Transactions 441
About OJEMDA
OJEMDA is a drug associated with $703,048 in payments to 101 healthcare providers, recorded across 441 transactions in the CMS Open Payments database. The primary manufacturer is Day One Biopharmaceuticals.
Payment data is available from 2024 to 2024. In 2024, $703,048 was paid across 441 transactions to 101 doctors.
The most common payment nature for OJEMDA is "Unspecified" ($511,343, 72.7% of total).
OJEMDA is associated with 3 research studies, including "A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations" ($313,784).